Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 1 month ago

Guidelines & Statements
AHA 25: HFpEF as an Adipose Tissue Disorder
Author(s): Milton Packer Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core… View more

Cardiovascular Renal Metabolic

Heart Failure
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
AHA 24 Late-Breaking Discussion: The ZODIAC Trial
Author(s): Harriette Van Spall , Kausik Ray Added: 1 year ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising… View more

Prevention & Chronic Conditions

MI/ACS
AHA 23: SUPER LIPID
Author(s): Alexander Fanaroff Added: 2 years ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more

Prevention & Chronic Conditions
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 2 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
New Horizons in Dyslipidaemia 2026
Start date: Feb 12, 2026 End date: Feb 12, 2026
New Horizons in Dyslipidaemia is a free-to-access, one-day virtual educational event on 12 February 2026, developed for healthcare professionals involved in cardiovascular risk assessment and lipid management.The programme will explore the rapidly evolving landscape of lipid management, addressing gaps between perceived and actual cardiovascular risk and the underutilisation of effective… View more

Prevention & Chronic Conditions
New Horizons in Dyslipidaemia 2026
Added: 2 weeks ago Source:  Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the… View more

Guidelines & Statements

Prevention & Chronic Conditions
Robert Eckel
Research Area(s) / Expertise: Job title: Professor of Medicine
Dr Robert Eckel is Professor of Medicine in the Division of Endocrinology, Metabolism and Diabetes at the University of Colorado Anschutz Medical Campus, Colorado, US.Dr Eckel has held appointments such as the Charles A. Boettcher II Endowed Chair in atherosclerosis research at the University of Colorado, director of the Lipid Clinic at University of Colorado Hospital, and program director of the… View more